<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00105092</url>
  </required_header>
  <id_info>
    <org_study_id>8670</org_study_id>
    <secondary_id>H6Q-MC-JCAQ</secondary_id>
    <nct_id>NCT00105092</nct_id>
  </id_info>
  <brief_title>Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.</brief_title>
  <official_title>A Phase II Evaluation of Oral Enzastaurin HCl in Second-and Third- Line Treatment of Patients With Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <brief_summary>
    <textblock>
      Enzastaurin given daily to patients with non-small cell lung cancer who have failed at least
      one prior therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To estimate the rate of progression-free survival at 6 months for patients receiving oral enzastaurin with NSCLC who are eligible for second-or third-line therapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics of enzastaurin using sparse sampling methodology in this population</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the QTc interval at anticipated steady state levels of enzastaurin (centrally collected 12-lead ECG on Day 1 of Cycle 2)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the objective response rate (complete response [CR] and partial response [PR])</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate time-to-event variables, such as overall survival time, duration of overall response (up to 1 year), and duration of stable disease (up to 1 year)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of enzastaurin in this patient population</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess PKCb expression by immunohistochemistry in readily available tumors from patients</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate enzastaurin's effect on patients' symptoms, functioning, and health-related quality of life using validated patient questionnaires</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore biomarkers relevant to tumor progression and PKCb signaling</measure>
  </secondary_outcome>
  <enrollment>50</enrollment>
  <condition>Non-Small-Cell Lung Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzastaurin HCL</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be at least 18 years old

          -  Must have been diagnosed with advanced or metastatic non-small cell lung cancer

          -  Must be able to visit the doctor's office every 28 days for 6 months or longer.

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  Have other significant medical problems as determined by your physician

          -  Are unable to swallow tablets

          -  Have a history of significant heart disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2005</study_first_submitted>
  <study_first_submitted_qc>March 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2005</study_first_posted>
  <last_update_submitted>April 27, 2007</last_update_submitted>
  <last_update_submitted_qc>April 27, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

